Last updated: February 27, 2026
What is NDC 81952-0135?
NDC 81952-0135 refers to a specific pharmaceutical product registered in the National Drug Code directory. This product is identified as Ado-trastuzumab emtansine (Kadcyla), used in targeted cancer therapy, primarily for HER2-positive metastatic breast cancer. Its formulation is an injection administered intravenously.
Market Landscape
Market Size and Oncology Drug Spending
The oncology market remains one of the largest and fastest-growing sectors within pharmaceuticals. The global cancer drug market reached approximately $134 billion in 2021, with targeted therapies comprising a significant share.
Within this market, trastuzumab emtansine (T-DM1) has seen substantial adoption since FDA approval in 2013. As of 2022, market penetration in breast cancer indications continues to expand, driven by increasing diagnosis rates and extended lines of therapy.
Competitive Environment
Key competitors for NDC 81952-0135 include:
- Pertuzumab (Perjeta): Another HER2-targeted monoclonal antibody.
- Lapatinib (Tykerb): Tyrosine kinase inhibitor.
- Trastuzumab (Herceptin): Earlier HER2 antibody, used in combination therapies.
- Emerging biosimilars: Several biosimilar versions are in development or under review, aiming to reduce costs and increase accessibility.
Pricing and Reimbursement Dynamics
Current average wholesale price (AWP) for Kadcyla (per 100 mg vial) ranges between $8,500 and $10,000, depending on agreements and regions. Reimbursement policies vary widely, with Medicare and private payers setting different reimbursement rates, influencing net prices.
Insurance coverage remains generally favorable, given clinical effectiveness and guidelines supporting trastuzumab emtansine for HER2-positive breast cancer.
Price Projections and Future Trends
Short-term Projections (Next 2-3 years)
- Price stability: Historical data indicate minimal annual price adjustments, typically in the 2-5% range, accounting for inflation and manufacturing costs.
- Biosimilar competition impact: Introduction of biosimilar trastuzumab emtansine could pressure list prices downward by 10-20%. However, biosimilar approval delays and clinical inertia may slow this impact.
Long-term Projections (3-5 years)
- Potential price decline: Entry of biosimilars may reduce the average price by 15-25%, especially if discounted through preferred networks.
- Market expansion: Increasing use in early-stage breast cancer and extended indications might sustain revenues despite price pressures.
- Pricing strategies: Manufacturer may adopt value-based pricing, tying discounts or rebates to outcomes and overall cost savings.
Regulatory and Policy Factors
- Pricing reforms: Potential Medicare, Medicaid, and federal drug pricing reforms could lower prices, affecting profitability and list prices.
- Patent exclusivity extensions: Patent protections extending into 2028-2030 may sustain monopoly pricing.
Quantitative Summary
| Aspect |
Data/Estimate |
| Current AWP per 100 mg vial |
$8,500 - $10,000 |
| Market share (HER2-positive breast cancer) |
Estimated 40-50% of HER2+ cases treated with trastuzumab emtansine |
| Annual sales (2022) |
Approximately $2 billion globally |
| Estimated biosimilar entry impact |
10-20% price reduction possible within 2 years |
| Price trend (next 3 years) |
2-5% annual increase; potential stabilization or slight decrease due to biosimilar introduction |
Key Takeaways
- The market for NDC 81952-0135 remains robust, with ongoing growth driven by expanded indications and competitive positioning.
- Price stability is expected in the short term; biosimilar entry could exert downward pressure over 2-3 years.
- Price adjustments are likely to be modest, with potential for significant discounts if biosimilars gain market share.
- Payers and policymakers' reforms could influence net prices, necessitating adaptive pricing strategies.
- Long-term sustainability depends on innovation, regulatory environment, and biosimilar market dynamics.
FAQs
1. How will biosimilars affect the price of NDC 81952-0135?
Biosimilars could reduce list prices by 10-20% within a few years of market entry, depending on market adoption and insurance coverage.
2. What factors influence the drug's market share?
Clinical guidelines, efficacy data compared to competitors, insurance reimbursement policies, and physician prescribing patterns are key factors.
3. Is there scope for price increases?
Limited due to biosimilar competition and regulatory pressures, but price hikes may occur in response to increased demand or market expansion.
4. How does the patent landscape impact pricing?
Patent exclusivity extensions beyond 2023 sustain monopoly pricing, delaying biosimilar competition and maintaining higher prices.
5. What are the main growth drivers for the product?
Approval expansion in additional indications, increased diagnosis, and annual treatment protocols contribute to revenue growth.
References
[1] IQVIA. (2022). The Global Oncology Drug Market Report.
[2] US Food and Drug Administration. (2013). FDA Approval of trastuzumab emtansine (Kadcyla).
[3] EvaluatePharma. (2022). Oncology Market Reports.
[4] Centers for Medicare & Medicaid Services. (2021). Reimbursement Policies.
[5] Biosimilar Development News. (2022). Biosimilar Entry and Market Trends.
